The Court dismissed Johnson & Johnson’s lawsuit, found that the company’s NIR stent did not infringe one patent of Johnson & Johnson, and found that the other Johnson & Johnson patent was invalid.
Johnson & Johnson recently filed a second lawsuit in Canada in which the company’s Express and Taxus Express stents are accused of infringing these same two patents.
Paul LaViolette, COO of Boston Scientific, said: “The ruling affirms our position that our products do not infringe these patents. We also believe our Express and Taxus Express coronary stents do not infringe as alleged by Johnson & Johnson and are hopeful the Court will reach the same conclusion.”